Primary Prevention of Clostridioides difficile Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70246 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Heather Valdin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology Oncology, Louisiana State University Health Sciences Center and Manning Family Children's, New Orleans, Louisiana,…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Vancomycin, Clostridium Infections, Anti-Bacterial Agents. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Background
Clostridioides difficile infection (CDI) poses a significant risk to pediatric hematopoietic stem cell transplant (HSCT) due to microbiome disruption, mucosal injury, and graft versus host disease (GVHD). While oral vancomycin prophylaxis (OVP) is effective for preventing recurrent CDI, evidence for its role in preventing initial infection is limited. Our institution employs empiric OVP during the first HSCT admission to prevent initial CDI.
Objectives
We sought to describe the incidence of CDI among pediatric HSCT recipients receiving OVP and to evaluate secondary outcomes related to OVP exposure.
Methods
We conducted a single center, retrospective observational study of 84 pediatric HSCT recipients at our institution receiving OVP during their initial transplant admission. Chart review captured demographics, transplant information, and clinical outcomes. The primary outcome was CDI incidence during hospitalization. Secondary outcomes included VRE infections, refractory CDI following cessation of OVP, and acute GI GVHD.
Results
Only one patient developed CDI (1.19%) while on OVP, despite universal exposure to high‐risk antibiotics among the entire cohort. No VRE infections were observed. Rates of GI aGVHD were consistent with national averages. Nine patients (10.7%) developed CDI after discontinuing OVP, all managed with standard treatment.
Conclusion
Empiric OVP during pediatric HSCT hospitalization was associated with a markedly low CDI incidence. Despite theoretical risks of microbiome disruption, no adverse effects were identified in this cohort, including long‐term follow‐up beyond 5 years. These findings support the safety and potential efficacy of OVP as primary CDI prophylaxis in pediatric HSCT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology Oncology, Louisiana State University Health Sciences Center and Manning Family Children's, New Orleans, Louisiana, USA.
- Louisiana State University Health Sciences Center School of Medicine, New Orleans, Louisiana, USA.
- Department of Pharmacy, Manning Family Children's, New Orleans, Louisiana, USA.
ORCID-Profile: Heather Valdin
Zitieren
APA
Valdin, H., Gray, B., Cook, G., Creamer, M., Yu, L., & LeBlanc, Z. (2025). Primary Prevention of Clostridioides difficile Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients. Pediatric Transplantation. https://doi.org/10.1111/petr.70246
Vancouver
Valdin H, Gray B, Cook G, Creamer M, Yu L, LeBlanc Z. Primary Prevention of Clostridioides difficile Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients. Pediatric Transplantation. 2025. doi:10.1111/petr.70246
BibTeX
@article{Valdin2025,
author = {Valdin, Heather and Gray, Blake and Cook, Gregory and Creamer, Mackenzie and Yu, Lolie and LeBlanc, Zachary},
title = {Primary Prevention of Clostridioides difficile Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70246}
}
EUVIMED